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Abstract: In twenty first century, the incidence of type 2 diabetes mellitus (DMt2) dramatically increases, 
followed by the number of patients suffering from its complications. Currently, diabetic kidney disease 
(DKD) is the leading cause of renal replacement therapy. Often, DMt2 is diagnosed after several years of 
duration, and irreversible organ damage can develop during that period. On the other hand, the early diag-
nosis of DKD in the preclinical phase, when glomerular filtration rate (GFR) is still maintained and there 
are no evident changes in urinalysis, gives the possibility of implementing the nephroprotective treatment 
that can significantly delay the progression of the disease. However, the diagnostic tests available in clinical 
practice, i.e. serum creatinine, estimated glomerular filtration rate (eGFR) and albuminuria have important 
limitations. There is a need for new, early and non-invasive biomarkers specific for kidney injury, allowing 
for differentiation between glomerular and tubular injury, and changing dynamically in response to the de-
gree of kidney damage. Hereby, we review the current knowledge about the novel and emerging biomarkers 
of kidney injury and their used for the diagnosis of DKD.
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Introduction
It is estimated that nearly 387 mln people in the world suffer from diabetes. Its preva-
lence exceeds 8,3% and gradually increases [1]. Diabetic kidney disease (DKD) has been 
regarded as one of the chronic complications of diabetes resulting from microangiopathy. 
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DKD is the most common cause of chronic kidney disease (CKD), leading over 
time to the necessity for renal replacement therapy [2]. Among patients with type 2 
diabetes mellitus (DMt2), CKD is one of the most common causes of hospitalisation, 
associated with cardiovascular events, cardiovascular mortality, and also total mortal-
ity [3]. It is also the only complication which incidence has not decreased despite the 
improvement in the methods of diabetes control during the last 20 years [4]. Thus, the 
strategy aiming at the decrease of CKD incidence and progression in DMt2 needs to 
be improved. 
Current criteria of DKD diagnosis
In nearly 70% of DMt2 patients, the coexisting insulin resistance and the diabetic envi-
ronment, exert different effects on kidneys in comparison with the changes observed in 
type 1 diabetes [5]. The long term hyperglycemia in poorly controlled diabetes, together 
with the coexisting hypertension and hyperlipidemia are considered the main causes 
of DKD progression in patients with DMt2 [5]. The recommendations published by 
the Kidney Disease Outcomes Quality Initiative (KDOQI) working group in 2002 [6] 
introduced the term DKD as one of the CKD forms, and the albumin concentration 
measured in 24-hour urine sample has been considered a standard for the assessment 
of kidney disease in the course of diabetes. However, urine albumin to creatinine ratio 
(UACR) measured in a spot urine sample may be used in routine care in order to es-
timate urine albumin excretion. Since 2007, KDOQI has recommended that increased 
UACR (formerly termed “micro-” or “macroalbuminuria”) should be confirmed by at 
least 2 further measurements performed in first morning urine samples [7]. 
Albuminuria is not specific for kidney injury in the course of DMt2. Increased 
urine albumin excretion is observed in glomerulopathies irrespective of the cause, as 
well as in medical conditions associated with increased vascular permeability, i.e. se-
vere infections or heart failure [8]. Moreover, increased albuminuria does not have to 
be caused by kidney injury, but may be associated with hyperfiltration as observed in 
febrile patients, in those with urinary tract infections, or in healthy people following 
significant physical activity. 
At present, the terms “microalbuminuria” and “macroalbuminuria” are not further 
recommended. The loss of albumin in urine in quantities of 30–300 mg/day should be 
considered a moderately increased albuminuria. Higher albumin loss in urine is con-
sequently called severely increased albuminuria. The former term “microalbuminuria” 
has incorrectly suggested the presence of “microalbumine” in urine, or could have 
been interpreted as the finding of minimal clinical importance, therefore it has been 
abandoned. According to the recommendations of Polish Diabetological Association 
published in 2015 [8], the laboratory tests that should be performed for the diagnosis 
and assessment of DKD include urine albumin excretion and serum creatinine mea-
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surements followed by the estimation of glomerular filtration rate (GFR) according to 
Modification of Diet in Renal Diseases (MDRD) or Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) equations. Screening towards increased albuminuria 
should be done in each patient with DMt2 at least once a year starting from the diagnosis 
of diabetes [8].
Pathophysiology of kidney damage in DMt2 
The morphological changes in the course of DKD involve the structures of glomeruli, 
including endothelial cells, basement membrane, podocytes and slit membrane. The 
mesangial expansion, increased numbers of interstitial cells and tubular lesions have 
also been observed [5]. However, there is only a weak association between the severi-
ty of morphological changes in kidneys and the routinely used laboratory and clinical 
markers of kidney injury (i.e. increased urine albumin and total protein, increased serum 
creatinine and decreased eGFR, high blood pressure) [5]. Moderately increased albumin-
uria (30–300 mg/g creatinine) is a first sign of DKD only in a part of patients. In about 
30% of DMt2 patients, the decrease in GFR occurs without increased albuminuria [9]. 
Moreover, it must be remembered that DKD is not the only cause of CKD among pa-
tients with diabetes. For a proper diagnosis, imaging tests, and in selected cases, his-
tological examination of kidney biopsy may be indicated apart from albuminuria and 
serum creatinine. Unfortunately, in routine clinical practice such tests may be difficult 
to perform. According to the data from the Polish registry of nephropathies diagnosed 
based on kidney biopsy (2009–2012) concerning DMt2 patients, DKD has been diag-
nosed in about 2% of biopsies, whereas 60% of biopsies resulted in the diagnosis of other 
nephropathies [10] (it must be remembered, however, that kidney biopsy as an inva-
sive procedure is not indicated in typical course of DKD). It should also be noted that 
obesity (often preceding DMt2) causes focal segmental glomerulosclerosis [11]. Thus, 
it would be interesting to investigate the existing and emerging biomarkers of kidney 
injury in the association to the specific lesions described following kidney biopsy and 
histological examination. On account of composite pathomechanism of kidney injury 
in DMt2 and in order to systematise knowledge about these processes, markers of DKD 
are divided into bioindicators of injury of kidney tract, injury of renal glomeruli, oxi-
dative stress and inflammation. Figure 1 presents the role of particular biomarkers for 
the pathogenesis of DKD in DMt2.
The ideal biomarker of kidney injury in DMt2
The diagnostic procedures used in kidney diseases, based on serum creatinine, urinalysis, 
and imaging tests may sometimes be inaccurate. Kidney biopsy, in turn, is associated with 
significant invasiveness. Serum creatinine concentrations depend not only on GFR, but 
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Fig. 1. Role of particular biomarkers for the pathogenesis of DKD in DMt2.
AGES — advanced glycation end-products; AGN II — angiotensin II; BMP — bone morphogenetic protein; CXCL-16 — chemokine 
(C-X-C motif) ligand 16; DKD — diabetes kidney disease; DMt2 — diabetes mellitus type 2; IL-6 — interleukin 6; IL-16 — interleukin 16; 
IL-18 — interleukin 18; KIM-1 — kidney injury molecule-1; L-FABP — liver type fatty acid binding protein; MPC-1 — monocyte 
chemoattractant protein-1; miRNAs — microRNAs; NAG — N-acetylo-b-D-glucosaminidase; NGAL — neutrophil gelatinase-associated 
lipocalin; NADPH — nicotinamide adenine dinucleotide phosphate (reduced); NOX 1-5 — NADPH oxidase 1-5; 8 OHdG pentosidine 
— 8-hydroxy-deoxy guanosine pentosidine; PKC — protein kinase C; RBP4 — retinol binding protein 4; ROS — reactive oxygen species; 
TGF-β1 — transforming growth factor beta 1; TNF-α — tumor necrosis factor α
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also on many additional factors, such as muscle mass, sex, age, diet or pharmacological 
treatment [12]. Also, creatinine in urine comes not only from glomerular filtration, but 
it is also excreted by the proximal tubule, which leads to falsely increased estimates of 
GFR based on creatinine clearence [12]. The ideal marker of GFR should be freely filtered 
in glomerulus, and neither excreted, nor absorbed in kidney tubules. Its concentrations 
should be easy to determine. It should be specific for kidney damage, and dynamically 
respond to the changes in GFR, also to the improvement in kidney function following 
treatment. It is expected that such a marker will be able to predict cardiovascular changes. 
A good biomarker of decreased GFR, together with a proper marker of tubular injury, 
would allow for the diagnosis of DKD (or the risk for DKD) in DMt2 patients without 
increased albuminuria before the kidneys are irreversibly damaged.
Albuminuria in the course of DMt2 
In the course of DKD, a damage to the filtration barrier leads to increased leak of plasma 
proteins with a molecular mass below 40 kDa, including albumin and transferrin. Such 
proteins are also filtered by the healthy renal glomeruli, although in lower amounts, and 
are reabsorbed by a proximal tubule [13]. Thus, increased excretion of such proteins in 
urine may be due to increased filtration in the or due to diminished reabsorption in the 
initial part of the nephron [13].
Currently, albuminuria is the gold standard in the diagnosis of DKD and the evalu-
ation of its advancement [8]. Albuminuria should be regarded as a marker of an ongo-
ing kidney damage, not as a risk factor for DKD [13]. Albuminuria is the independent 
predictor of cardiovascular and renal risk in diabetic patients [8]. However, about 30% 
of DMt2 patients with renal failure do not have albuminuria [9]. Among DMt2 patients 
without albuminuria or proteinuria, advanced glomerulosclerosis has been observed 
in kidney bioptates [14]. Also, the cut-off value for increased albuminuria is a matter 
of debate. The cut-off value for UACR of 30 mg/g seems too high, and many research-
ers consider UACR above 15 mg/g as a sign of kidney pathology or kidney risk [15]. 
Most recommendations for early nephroprotection in DMt2 are aimed at controlling 
albuminuria. Facing the increasing numbers of patients with DKD, there is a need for 
the early biomarkers of kidney injury, that may be used in patients without increased 
albuminuria, or that would precede the increase in albuminuria.
New biomarkers of DKD
The promising biomarkers in the field include urinary neutrophil gelatinase-associated 
lipocalin (NGAL), kidney injury molecule-1 (KIM-1), serum cystatin C (CysC), uro-
modulin (UMOD), urinary N-acetylo-beta-D-glucosaminidase (NAG), liver type fatty 
acids binding protein (L-FABP) and serum interleukin 18 (IL-18). 
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Neutrophil gelatinase-associated lipocalin 
NGAL, also known as lipocalin 2, is a 25 kDa secretory protein belonging to the lipoca-
lin family, detected in neutrophils’ granules [16]. In response to renal ischemia or toxic 
injury, NGAL expression significantly increases in the ascending limb of the loop of 
Henle. Urine NGAL concentrations are also correlated with its serum concentrations [17]. 
NGAL has been studied mainly as a biomarker of acute kidney injury (AKI). In AKI, 
increased urinary NGAL (uNGAL) concentrations have been observed already after 
4–6 hours from injury, thus NGAL has been regarded a “renal troponin” [18–20]. In 
CKD, including DKD, NGAL is considered as a diagnostics and prognostic marker. 
Bolignano et al. [21] observed that uNGAL increased and correlated with the advance-
ment of kidney disease in patients with DKD both with and without albuminuria. In 
the Chronic Renal Insufficiency Cohort (CRIC) Study [22], in patients with CKD stage 
G2-G4, increased uNGAL reflected the risk of cardiovascular complications. However, 
Helmersson et al. [23] observed high biological variation of uNGAL among patients with 
CKD due to tubular disorders, therefore they recommend both the assessment of uNGAL 
concentration and the calculation of uNGAL to urine creatinine ratio (uNGAL/uCr). 
In pathophysiology of DKD, NGAL may play an important role in adaptation of tubu-
lar cells to the damaging influence of diabetic environment. Summarizing, uNGAL can 
become a useful and non-invasive tool for the evaluation of kidney function, overtaking 
the classic markers, i.e. albuminuria or eGFR [21, 24]. It seems that a useful strategy 
in an evaluation of kidney disease in DMt2 patients would include the determination 
of an initial uNGAL concentration and uNGAL/uCr value and then the monitoring of 
their changes [24].
Kidney injury molecule-1
KIM-1 seems to be another promising biomarker of tubular injury. It is a type 1 trans-
membrane glycoprotein containing in its extracellular part the immunoglobulin and the 
mucous domains [25]. It is expressed in proximal renal tubule in response to hypoxia 
or injury, and is not detected in healthy people [26, 27]. Urinary KIM-1 is increased in 
AKI from the first day after toxic or ischemic injury [28]. However, KIM-1 expression 
in renal tubules has been also observed in the course of the focal glomerulosclerosis, 
IgA nephropathy, or membranoproliferactive glomerulonephritis [29, 30]. On the ba-
sis of these observations it has been suggested that KIM-1 can serve as a biomarker of 
chronic tubular injury [29, 30]. Currently, studies are ongoing on KIM-1 usefulness as 
a diagnostic marker in CKD. Following 3.5-year observation of patients with DKD, it has 
been shown that the increase of urinary KIM-1 correlates positively with albuminuria 
and negatively with GFR changes, however, it does not correlate with HbA1c [31]. In 
turn, Fu et al. [32] reported higher urinary KIM-1 in 101 patients with DMt2 observed 
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for 5 years as compared with the control group, however, they did not confirm the cor-
relations with UACR or eGFR. The available data are insufficient for the assessment of 
KIM-1 usefulness as a diagnostic tool in DKD, in particular among patients without 
albuminuria. Further studies are necessary, especially in the Caucasian population. 
Cystatin C 
CysC is a single chain 120 amino acid polypeptide, belonging to the cysteine proteinases 
inhibitors. It is freely filtered by glomeruli, then reabsorbed and metabolised in proxi-
mal tubules [33]. Its concentrations in serum, unlike creatinine, do not depend on the 
muscle mass neither the diet [33]. The determination of serum CysC is usefull for early 
detection of the decrease in glomerular filtration rate. A formula utilizing both serum 
creatinine and serum CysC allows for a precise estimation of GFR [34]. According to 
the 2012 KDIQO guidelines, serum CysC should be determined in adults with eGFR 
between 45 and 59 ml/min/1.73 m2 and without other signs of renal disease, in order 
to confirm CKD [35]. In patients with DKD, Woo et al. [36] reported higher useful-
ness of GFR estimation with the use of serum CysC than serum creatinine. Moreover, 
in Chinese patients with DMt2 [37] and in the study of Triki et al. [38] serum CysC 
predicted cardiovascular complications. The promising report of Garg et al. [39] has 
shown increased CysC concentrations in patients with glucose intolerance and without 
albuminuria. According to current knowledge, serum CysC should be used for early 
detection of kidney disease as well as for verification of GFR estimates based on serum 
creatinine [8].
Uromodulin
UMOD, also known as Tamm-Horsfall’s protein, is a glycoprotein synthesized exclusively 
in kidneys, where it is expressed in a thick ascending limb of the loop of Henle and in 
the initial segment of the distal tubule. Following its proteolysis, it is released to urine 
under physiological conditions and is a most abundant urinary protein in healthy people, 
however, it is also detectable in serum [40]. Urinary UMOD has been reported to prevent 
urinary tract infections and crystallization of salts [40]. In 1978, pathological localization 
of UMOD in kidneys has been detected in tubulointerstitial diseases, including medullary 
cystic disease, chronic pyelonephritis and hydronephrosis [41]. More recently, interesting 
observations have been provided by the human genome-wide association studies, which 
identified the associations between UMOD gene mutations and the increased risk of hyper-
tension, kidney stones and CKD [42]. Prajczer et al. [43] has shown negative correlations 
between urinary UMOD concentrations and serum creatinine and positive correlation 
with eGFR. Also, Zhou et al. [44] reported that low urinary UMOD in the initial stages 
of CKD predicted fast GFR decrease among patients with IgA nephropathy. In the last 
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study, urinary UMOD correlated with the advancement of tubular atrophy and interstitial 
tissue fibrosis [44]. The last report is promising, however, more evidence is necessary in 
order to assess the usefulness of urinary or serum UMOD as the early markers of CKD.
N-acetylo-beta-D-glucosaminidase 
NAG is the enzyme that is not filtered in renal glomeruli, and its increased activity in 
urine appears following toxic injury of renal tubules [45]. In diabetic patients, positive 
correlations have been observed between increased NAG activity in urine and albu-
minuria, diabetes duration, poor diabetes control, serum CysC and urine NGAL [46]. 
In the study of Sheira et al. [47] conducted in a group of 50 DMt2 patients, urine NAG 
positively correlated with UACR, serum creatinine, and HbA1c. Moreover, urine NAG 
activity was associated with the advancement of kidney disease in DMt2. NAG seems 
to be the promising DKD marker, increased already in a preclinical DKD, before sig-
nificant increase in albuminuria. However, there is a need for further research on this 
marker in Caucasian population. 
Liver type fatty acid binding protein 
L-FABP is a protein expressed in hepatocytes as well as in the cells of the nephron prox-
imal tubules [48], which appears in urine following tubular injury. Fergusson et al. [49] 
reported the role of L-FABP as a biomarker of AKI. Higher urine concentrations of 
L-FABP have been observed in DMt2 patients as compared with healthy individuals; 
moreover, it correlated with increasing albuminuria and decreasing GFR [50, 21]. In the 
study of Nauta et al. [51], among the measured markers of tubular injury, L-FABP was 
the most strongly correlated with eGFR. L-FABP seems the promising marker of DKD, 
that may be helpful in detecting the preclinical stages of the disease. 
Interleukin 18
IL-18 is a cytokine produced mainly by macrophages. The first known function of IL-18 
was a strong stimulation of T lymphocytes and NK cells to the production of interfer-
on γ [52]. The cytokine is also involved in the polarisation of immune response [52]. 
Apart from the physiological role, IL-18 has been associated with severe inflammatory 
reactions. Also, its pathophysiological role in DMt2 has been suggested [53]. In a group 
of 151 patients with DMt2, Moriwaki et al. [54] observed significantly increased serum 
IL-18 concentrations in comparison with the control group. Currently, the research 
are ongoing aimed at the evaluation of IL-18 as the early marker of DKD. Interesting 
observations were made by Szeto et al. [55] among 220 patients with DMt2: increased 
IL-18 correlated with the cardiovascular mortality. 
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New trends in diagnosing DKD 
Oxidative stress and novel therapeutic targets in DKD
There are several mechanisms in which hyperglycemia acts in a damaging way on both 
the endothelial cells and the epithelial cells of renal tubules, including increased polyol 
pathway flux, increased advanced glycation end-product formation, activation of pro-
tein kinase C, and increased hexosamine pathway flux. The common element linking 
these mechanisms is an increased production of superoxide by the mitochondrial elec-
tron-transport chain [56]. The overproduction of reactive oxygen species (ROS) results 
in the oxidative stress leading among others to renal tubular injury and the interstitial 
tissue fibrosis in DMt2 [56]. NADPH oxidase plays a key role in the oxidative stress. 
The enzyme has several isoforms, of which the NOX-4 seems the most important in 
the mechanism of ROS generation [57]. The animal studies by Thallas-Bonke et al. [58], 
revealed the advantageous effect of NOX-4 gene deletion on the progression of DKD. 
Further studies are needed to evaluate the associations between NOX isoforms and the 
DKD progression.
Dysfunction of podocytes in DKD pathogenesis
In the search for early DKD markers, it has been observed that podocyturia as well as 
urine excretion of proteins associated with podocytes can be a source of early DKD bio-
markers. Wang et al. [59] has shown the presence of nephrin and synaptopodin in urine 
of patients with DMt2 with proteinuria and reduced GFR. The results of Zhao et al. [60] 
are also promising. The study suggested a role of the CXCL-16 ligand for C-X-X chemok-
ines, taking part in the LDL metabolism within the podocytes, as the early biomarker 
of renal injury in DMt2.
MicroRNAs
The microRNAs (miRNAs) seem to be promising as the markers of renal fibrosis in the 
course of DKD. Xu et al. [61] has reported the role of miRNAs: miR-216A, miR-217, 
miR-192, miR-377, miR-21, miR-29c in DKD prognosis. The increased concentration 
of miR-21 has been shown in kidney bioptates from patients with DKD [62].
Proteomics as the promising DKD diagnostic and prognostic method
The proteomic methods utilizing mass spectrometry seems to have a great potential in 
providing data on protein profiles constituting the “finger print” of the diseases [11, 63]. 
The methods allowed for introducing several biomarkers of AKI and CKD, present in 
urine, blood or tissues. The proteomics has been termed a „liquid kidney biopsy”, as 
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a non-invasive tool that could potentially be used in a preclinical phase of kidney dis-
eases [63]. Rossing et al. [64] have identified the peptide profiles in urine in the group 
of patients with DMt1 and DMt2, which seem to have been better predictors of DKD 
progression than albuminuria. Also, the method identified 12 metabolites of glucose 
metabolism in the glycolytic pathway, which possess the prognostic value for DKD in 
DMt2. The proteomics in nephrology has the multidirectional character and constitute 
the promising method of searching for DKD biomarkers. However, in order to define 
the diagnostic sensitivity and specificity of the markers, further studies are needed, ver-
ifying the results on the larger groups of patients.
Conclusions
Due to the significant diversity of histopathological changes observed in kidneys in 
the course of DMt2 and the accompanying diverse clinical picture of DKD, additional 
diagnostic tools are necessary, except for eGFR and albuminuria. The kidney injury in 
DMt2 is often irreversible, especially in patients with decreased GFR and increasing al-
buminuria. Early diagnosis and multidirectional treatment constitute the only effective 
way of stopping the progression of kidney disease and improving prognosis. In clinical 
practice, the intensive treatment undertaken in the advanced disease may only slow down 
its progression. Due to the insufficient diagnostic sensitivity of clinically used markers, 
the research are ongoing to identify the new markers allowing for early diagnosis of the 
disease and introducing the proper treatment in the preclinical phase of diabetic kidney 
injury. However, further research is needed before implementing the novel markers in 
wide clinical practice.
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